Colorectal Cancer

>

Latest News

Novel Therapy Yields Anti-Tumor Activity in KRAS G12C–Mutated CRC
Novel Therapy Yields Anti-Tumor Activity in KRAS G12C–Mutated CRC

May 31st 2025

As a single agent or in combination, MK-1084 showed promising efficacy and safety results for patients with KRAS G12C–mutated CRC.

Emergent alteration patterns were similarly diverse across treatment arms in the phase 3 CodeBreaK 300 study.
Genomic Alterations May Cause Resistance to Sotorasib KRAS G12C+ CRC Combo

May 31st 2025

Nivolumab/Ipilimumab Sustain Benefit Vs Chemo or Nivolumab in MSI-H/dMMR CRC
Nivolumab/Ipilimumab Sustain Benefit Vs Chemo or Nivolumab in MSI-H/dMMR CRC

May 31st 2025

Anlotinib/chemotherapy showed comparable efficacy vs bevacizumab/chemotherapy in patients with RAS/BRAF wild-type metastatic colorectal cancer.
Anlotinib Shows Noninferiority to Bevacizumab in RAS/BRAF Wild-Type mCRC

May 31st 2025

Updated findings from BREAKWATER support encorafenib plus cetuximab and chemotherapy as a new standard of care in BRAF V600E-mutated metastatic CRC.
PFS Improves in BRAF V600E+ CRC With Encorafenib Combo

May 30th 2025

Video Series
Video Interviews
Podcasts
The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.
Oncology pharmacist Jagoda Misniakiewicz, PharmD, discusses the potential efficacy and safety profile of fruquintinib in patients with metastatic CRC.
Surgical oncologists from Cleveland Clinic discuss the National Accreditation Program for Rectal Cancer and its aim to improve patient outcomes.
Gregory Charak, MD, discusses how modalities like laparoscopic surgery and neoadjuvant immunotherapy may benefit patients with colorectal cancer.
New studies and treatment options prove to be effective in treating metastatic CRC, notes Joleen Hubbard, MD.
Personalized therapy tailored for mutation status is something to expect in the coming years for colorectal cancer treatment, notes Tanios S. Bekaii-Saab, MD.
New treatment updates could help find more patient subtypes to target and treat in the world of CRC.
Arvind N. Dasari, MD, and Cathy Eng, MD, discuss clinical trial data that may support the FDA approval of fruquintinib in metastatic colorectal cancer, and how it may impact the standard of care.
Lead author Ibrahim Halil Sahin, MD, spoke with CancerNetwork® about his work investigating postoperative circulating tumor DNA dynamics in early-stage colon cancer as part of the CIRCULATE-US trial published in the journal ONCOLOGY®.

More News